Anti-Ipilimumab ELISA Assay Kit
The Anti-Ipilimumab ELISA Assay Kit is For Research Use Only
Size: 12×8 wells
Sensitivity: <10 ng/ml
Standard Range: 10-640 ng/ml
Incubation Time: 2.25 hours
Sample Type: Serum, Plasma, Cell Culture Supernatants
Sample Size: 100 µl
Alternative Name: Yervoy
Ipilimumab (trade name Yervoy) is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that down regulates the immune system. Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, an inhibitory mechanism interrupts this destruction. Ipilimumab turns off this inhibitory mechanism and allows CTLs to function. Ipilimumab was approved by the U.S. FDA in 2011 for the treatment of melanoma, a type of skin cancer. It is undergoing clinical trials for the treatment of non-small cell lung carcinoma (NSCLC), small cell lung cancer (SCLC), bladder cancer and metastatic hormone-refractory prostate cancer. Anti-Drug Antibodies (ADA) may induce unwanted side effects in biopharmaceuticals.
Hence, ADA has been subjected to increase in scrutiny by the regulatory authorities using immunogenicity safety studies. ADA has been observed in pre-clinical and clinical studies, resulting in significant changes in toxicology, pharmacokinetics and efficacy. These effects result from the generation of drug-induced (neutralizing) autoantibodies against Ipilimumab and can be responsible for allergic reaction, or even anaphylactic shock. This ELISA kit detects antibodies for Anti-Ipilimumab and may be used for monitoring immunogenicity.